CXCR2 and chronic obstructive pulmonary disease: AZD5069 (AstraZeneca) is a selective CXCR2 antagonist that has been tested for safety and efficacy in pre-clinical and clinical studies of COPD and asthma (O'Byrne et al., 2016; Pedersen et al., 2018).